361 related articles for article (PubMed ID: 32791086)
1. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Spino C; Kaskel FJ; Friedman A; Moxey-Mims MM; Fine RN; Gassman JJ; Kopp JB; Walsh L; Wang R; Gipson DS
Am J Kidney Dis; 2021 Feb; 77(2):216-225. PubMed ID: 32791086
[TBL] [Abstract][Full Text] [Related]
2. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Nachman PH; Kretzler M; Spino C; Komers R; Tuller S; Perumal K; Massengill SF; Kamil ES; Oh G; Selewski DT; Gipson P; Gipson DS
Clin J Am Soc Nephrol; 2018 Mar; 13(3):414-421. PubMed ID: 29167190
[TBL] [Abstract][Full Text] [Related]
3. Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS.
Hogg RJ; Friedman A; Greene T; Radeva M; Budisavljevic MN; Gassman J; Gipson DS; Jefferson JA; John EG; Kaskel FJ; Moudgil A; Moxey-Mims M; Ortiz LA; Schelling JR; Schnaper W; Srivastava T; Trachtman H; Vehaskari VM; Wong C; Woronieki RP; Van Why SK; Zolotnitskaya A
Clin J Am Soc Nephrol; 2013 Feb; 8(2):211-8. PubMed ID: 23143503
[TBL] [Abstract][Full Text] [Related]
4. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.
Laurin LP; Gasim AM; Derebail VK; McGregor JG; Kidd JM; Hogan SL; Poulton CJ; Detwiler RK; Jennette JC; Falk RJ; Nachman PH
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1752-1759. PubMed ID: 27445167
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis.
Chiou YY; Lee YC; Chen MJ
Curr Med Res Opin; 2017 Aug; 33(8):1389-1399. PubMed ID: 28436233
[TBL] [Abstract][Full Text] [Related]
6. Steroid resistant focal segmental glomerulosclerosis: effect of arterial hyalinosis on outcome: single center study.
Soliman AR; Maamoun H; Soliman H; Ahmed RM
Rom J Intern Med; 2021 Jun; 59(2):127-133. PubMed ID: 33565308
[No Abstract] [Full Text] [Related]
7. Adiponectin in children and young adults with focal segmental glomerulosclerosis.
Sethna CB; Boone V; Kwok J; Jun D; Trachtman H
Pediatr Nephrol; 2015 Nov; 30(11):1977-85. PubMed ID: 26115618
[TBL] [Abstract][Full Text] [Related]
8. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN; Alpers CE; Barratt J; Bieler S; Canetta P; Chae DW; Coppock G; Diva U; Gesualdo L; Heerspink HJL; Inrig JK; Kirsztajn GM; Kohan D; Komers R; Kooienga LA; Lieberman K; Mercer A; Noronha IL; Perkovic V; Radhakrishnan J; Rote W; Rovin B; Tesar V; Trimarchi H; Tumlin J; Wong MG; Trachtman H;
N Engl J Med; 2023 Dec; 389(26):2436-2445. PubMed ID: 37921461
[TBL] [Abstract][Full Text] [Related]
9. Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental Glomerulosclerosis.
Gipson DS; Troost JP; Spino C; Attalla S; Tarnoff J; Massengill S; Lafayette R; Vega-Warner V; Adler S; Gipson P; Elliott M; Kaskel F; Fermin D; Moxey-Mims M; Fine RN; Brown EJ; Reidy K; Tuttle K; Gibson K; Lemley KV; Greenbaum LA; Atkinson MA; Hingorani S; Srivastava T; Sethna CB; Meyers K; Tran C; Dell KM; Wang CS; Yee JL; Sampson MG; Gbadegesin R; Lin JJ; Brady T; Rheault M; Trachtman H
JAMA Netw Open; 2022 Aug; 5(8):e2228701. PubMed ID: 36006643
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.
Gipson DS; Trachtman H; Kaskel FJ; Radeva MK; Gassman J; Greene TH; Moxey-Mims MM; Hogg RJ; Watkins SL; Fine RN; Middleton JP; Vehaskari VM; Hogan SL; Vento S; Flynn PA; Powell LM; McMahan JL; Siegel N; Friedman AL
Kidney Int; 2011 Mar; 79(6):678-685. PubMed ID: 21178977
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial of focal segmental glomerulosclerosis in children and young adults.
Gipson DS; Trachtman H; Kaskel FJ; Greene TH; Radeva MK; Gassman JJ; Moxey-Mims MM; Hogg RJ; Watkins SL; Fine RN; Hogan SL; Middleton JP; Vehaskari VM; Flynn PA; Powell LM; Vento SM; McMahan JL; Siegel N; D'Agati VD; Friedman AL
Kidney Int; 2011 Oct; 80(8):868-78. PubMed ID: 21734640
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trials in FSGS: Past Challenges and New Trial Designs.
Gipson D
Semin Nephrol; 2016 Nov; 36(6):453-459. PubMed ID: 27987544
[No Abstract] [Full Text] [Related]
13. Urinary miR-196a predicts disease progression in patients with chronic kidney disease.
Zhang C; Liang S; Cheng S; Li W; Wang X; Zheng C; Zeng C; Shi S; Xie L; Zen K; Liu Z
J Transl Med; 2018 Apr; 16(1):91. PubMed ID: 29636065
[TBL] [Abstract][Full Text] [Related]
14. Primary FSGS in Nephrotic Adults: Clinical Profile, Response to Immunosuppression and Outcome.
Bagchi S; Agarwal S; Kalaivani M; Bhowmik D; Singh G; Mahajan S; Dinda A
Nephron; 2016; 132(2):81-5. PubMed ID: 26799973
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of collapsing focal segmental glomerulosclerosis.
Raja R; Nada R; Yadav AK; Kumar A; Goyal A; Kumar V; Rathi M; Kohli HS; Gupta KL; Sakhuja V; Jha V
Ren Fail; 2016 Jul; 38(6):894-8. PubMed ID: 27266801
[TBL] [Abstract][Full Text] [Related]
16. Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults.
Greenwood AM; Gunnarsson R; Neuen BL; Oliver K; Green SJ; Baer RA
Nephrology (Carlton); 2017 Jul; 22(7):520-530. PubMed ID: 27170059
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.
Cattran DC; Appel GB; Hebert LA; Hunsicker LG; Pohl MA; Hoy WE; Maxwell DR; Kunis CL
Kidney Int; 1999 Dec; 56(6):2220-6. PubMed ID: 10594798
[TBL] [Abstract][Full Text] [Related]
18. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.
Mariani LH; Bomback AS; Canetta PA; Flessner MF; Helmuth M; Hladunewich MA; Hogan JJ; Kiryluk K; Nachman PH; Nast CC; Rheault MN; Rizk DV; Trachtman H; Wenderfer SE; Bowers C; Hill-Callahan P; Marasa M; Poulton CJ; Revell A; Vento S; Barisoni L; Cattran D; D'Agati V; Jennette JC; Klein JB; Laurin LP; Twombley K; Falk RJ; Gharavi AG; Gillespie BW; Gipson DS; Greenbaum LA; Holzman LB; Kretzler M; Robinson B; Smoyer WE; Guay-Woodford LM;
Am J Kidney Dis; 2019 Feb; 73(2):218-229. PubMed ID: 30420158
[TBL] [Abstract][Full Text] [Related]
19. Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.
Cheng P; Xie Q; Liu S; Liu X; Wang L; Hao CM
Rev Assoc Med Bras (1992); 2024; 70(4):e20230871. PubMed ID: 38716932
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.
Trachtman H; Vento S; Herreshoff E; Radeva M; Gassman J; Stein DT; Savin VJ; Sharma M; Reiser J; Wei C; Somers M; Srivastava T; Gipson DS
BMC Nephrol; 2015 Jul; 16():111. PubMed ID: 26198842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
